MedTrace Logo

Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe

NCT01791361 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 439

Last updated 2022-09-10

No results posted yet for this study

Summary

This non-interventional retrospective medical record review study will assess the prevalence of KRAS testing and the impact of the KRAS test result on patterns of Vectibix use in patients with metastatic colorectal cancer (mCRC) treated with Vectibix in selected European countries over 3 rounds. As the optimal use of Vectibix also requires accurate KRAS mutation testing, this study will also assess data from the laboratory that performed the KRAS test. The study will also monitor changes in the pattern of Vectibix treatment between the different rounds of the study.

Conditions

Interventions

OTHER

Other

No intervention other than routine medical care

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-19
Primary Completion
2015-06-02
Completion
2015-06-02

Countries

  • Belgium
  • Czechia
  • Denmark
  • France
  • Germany
  • Italy
  • Netherlands
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01791361 on ClinicalTrials.gov